Copyright
©The Author(s) 2025.
World J Hepatol. Sep 27, 2025; 17(9): 107705
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.107705
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.107705
Table 1 Classification, genetic basis, and clinical features of major porphyria subtypes
| Porphyria type | Enzyme deficiency | Gene | Inheritance | Primary site of synthesis | Accumulated porphyrin intermediate | Neurovisceral symptoms | Cutaneous symptoms | Liver involvement |
| Acute hepatic porphyrias | ||||||||
| ADP | ALA-dehydratase | ALAD | AR | Liver | ALA | + | -/+ | - |
| AIP | PBG deaminase | HMBS | AD | Liver | ALA, PBG | ++ | - | - |
| HCP | Coproporphyrinogen oxidase | COPROX | AD | Liver | ALA, PBG, coproporphyrin III | + | + | - |
| VP | Protoporphyrinogen oxidase | PROTOX | AD | Liver | ALA, PBG, coproporphyrin III, protoporphyrin IX | + | + | + |
| Hepatic cutaneous porphyrias | ||||||||
| PCT | Uroporphyrinogen decarboxylase | UROD | AD/sporadic | Liver | Urinary porphyrins, carboxylated porphyrin | - | ++ | + |
| HEP | Uroporphyrinogen decarboxylase | UROD | AR | Liver | Urinary porphyrins, carboxylated porphyrin | - | ++ | + |
| Erythropoietic cutaneous porphyrias | ||||||||
| CEP | Uroporphyrinogen III synthase | UROS | AR | Bone marrow | Urinary porphyrin 1, fecal porphyrin I | - | ++ | - |
| EPP | Ferrochelatase | FECH | AR | Bone marrow | Protoporphyrin IX | - | ++ | + |
| XLP | ALA synthase 2 | ALAS2 | X-linked | Bone marrow | Protoporphyrin IX, Zn-bound protoporphyrin IX | -/+ | + | + |
Table 2 Categorization of high-risk pharmacological agents in porphyria
| Drug category | Drug name |
| Psychiatric drugs | Phenobarbital, Phenytoin, Chlorzoxazone, Diphenhydramine, Carbamazepine, Sodium Valproate, Oxcarbazepine, Ergometrine, Methyldopa, Flurazepam |
| Intravenous anesthetics | Thiopental sodium |
| Antimicrobial drugs | Voriconazole, Itraconazole, Fluconazole, Trimethoprim, Chloramphenicol, Erythromycin, Sulfasalazine, Sulfamethoxazole, Rifampicin, Rifapentine, Ritonavir, Nevirapine, Dapsone, Furantoin |
| Hormonal drugs | Nandrolone, Estrogen drugs, Oral contraceptives, Mifepristone, Danazol |
| Other drugs | Spironolactone, Praziquantel, Hydralazine |
- Citation: Zeng T, Huang SY, Chen JN, Pang JH, Chong YT, Li XH. Pathogenesis and clinical management of liver damage in porphyrias: Mechanisms and therapeutic approaches. World J Hepatol 2025; 17(9): 107705
- URL: https://www.wjgnet.com/1948-5182/full/v17/i9/107705.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i9.107705
